Issue 2018/01
Mar, 2018
Dear All,
Digitalisation, Agility, Internet of Things, Industry 4.0 etc.
There are so many buzz words about trends and changes in the air – and everybody defines them differently.

But one thing is clear: Times are changing – and this change process accelerates more and more. It creates many challenges to the people – but also many chances. And what you see now in front of you is definitively a great chance.

The new DiaLog is easier to access, faster, distributable, has deeper content in areas interesting for you, comes more frequently – and by combining all these attributes we are sure it will help you to pick better and more precisely the important informations for you.
Made to enhance the success of your business with DiaSys products – this was the intention and we hope that you can agree that the intention is fulfilled.

If yes: please talk to others - If not: please talk to us!
You can contact us via

Greetings from Holzheim

Dr. Guenther Gorka
Managing Director and CEO DiaSys GmbH
DiagNite 4.0
India is a huge subcontinent and the now 160 DiaSys India colleagues are spread all over the country. Once a year, the DiagNite is the opportunity for all the employees of DiaSys India to get together during 3 days. After DiaSys India celebrated its 3rd anniversary, DiagNite 4.0 was perfectly organized in a resort 50km south of Mumbai.

Find out more
 ß-hydroxybutyrate not only an indicator for diabetic ketoacidosis but also a cancer inhibitor?
 Lipoprotein (a): Limitation and inaccuracy of recommended mean conversion factor 2.4 to calculate Lp(a) values from mg/dL to nmol/L
The XX lipid meeting in Leipzig (Germany) was founded more than 20 years ago and has developed into an established forum for scientific discussion and interdisciplinary collaboration in all relevant areas of lipid metabolism and diseases caused by lipid disorders. DiaSys had the privilege to present a scientific poster at the XX lipid meeting in Leipzig, December 2017. The objective of the poster was to examine the accuracy of the recommended mean conversion factor 2.4 to calculate Lp(a) values from mg/dL to nmol/L by using the ready to use immunoturbidimetric, Lp(a) 21 FS, reagent with the option to report in mg/dL or nmol/L.

 IVD Regulation: Next Steps?
A new In-Vitro Diagnostics Regulation (2017/746/EC) has been issued in 2017. The transition period for the regulation to becoming fully effective is 5 years.
In this edition of DiaLog we want to inform you about the obligations of distributors according Regulation 2017/746 of the European Parliament and of Council of 05 April 20107.

Take a look and be prepared.

Find out more
MEDLAB 2018 in Dubai
Since many years we take the opportunity to present our products and meet our customers at MEDLAB in Dubai. MEDLAB opened its doors to more than 25,000 attendees from more than 129 countries.

Find out more
From Holzheim to Asia-Pacific
As a leading specialist in the development and manufacturing of diagnostic system solutions, DiaSys is well known to customers in more than 100 countries. DiaSys stands for highest quality and reliable performance of clinical chemistry and immunoturbidimetric reagents. This is one of the reasons, why customers all over the world choose DiaSys as a trusted partner.

Find out more
April 23 – 27, 2018
Cuba Salud, La Habana Cuba
Booth No. 33-35

Visit website
If you have any questions or suggestions please contact:

Executive board:
Dr. Günther Gorka,
Dr. Jan Gorka,
Peter Zöller
DiaSys Diagnostic Systems GmbH
Alte Strasse 9 | 65558 Holzheim | DE

Fon: +49 (0) 64 32 - 91 46-0
Fax: +49 (0) 64 32 - 91 46-32
Register court: AG Montabaur
Registration number: HRB 7106

Sales tax identification number according to
§ 27 a VAT registration number: DE 148-404-658